Page last updated: 2024-12-06

kerriamycin b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

kerriamycin B: from a streptomycete; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID443819
CHEMBL ID4858734
CHEBI ID32279
MeSH IDM0134968

Synonyms (10)

Synonym
kerriamycin b
98474-21-6
urdamycin a
CHEBI:32279
(1r)-1,5-anhydro-2,6-dideoxy-3-o-{(2s,5s,6s)-5-[(2,6-dideoxy-beta-d-arabino-hexopyranosyl)oxy]-6-methyltetrahydro-2h-pyran-2-yl}-1-[(3r,4ar,12bs)-3,4a,8-trihydroxy-12b-{[(2s,5s,6s)-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yl]oxy}-3-methyl-1,7,12-trioxo-1,2
(3r,4ar,12bs)-9-[(2r,4r,5r,6r)-4-[(2s,5s,6s)-5-[(2s,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]-3,4a,8-trihydroxy-12b-[(2s,5s,6s)-5-hydroxy-6-methyloxan-2-yl]oxy-3-methyl-2,4-dihydrobenzo[a]anthracene-1
Q27114848
(3r,4ar,12bs)-9-[2,6-dideoxy-3-o-[(2s,5s,6s)-5-[(2,6-dideoxy-beta-d-arabino-hexopyranosyl)oxy]tetrahydro-6-methyl-2h-pyran-2-yl]-beta-d-arabino-hexopyranosyl]-3,4,4a,12b-tetrahydro-3,4a,8-trihydroxy-3-methyl-12b-[[(2s,5s,6s)-tetrahydro-5-hydroxy-6-methyl-
CHEMBL4858734
AKOS040755284
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
angucycline antibioticAny angucycline that exhibits antibiotic activity.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1755131Toxicity in axolotl embryo at 10 uM after 7 days by tail regeneration assay2021Journal of natural products, 07-23, Volume: 84, Issue:7
Himalaquinones A-G, Angucyclinone-Derived Metabolites Produced by the Himalayan Isolate
AID1859350Inhibition of His-tagged SUMO1/GST-tagged Aos1/Uba2/His-tagged Ubc9 (unknown origin)-mediated recombinant His/T7-tagged RanGAP1-C-terminal fragment SUMOylation expressed in Escherichia coli BL21 (DE3) assessed as reduction in Ubc9-SUMO level in presence o2022European journal of medicinal chemistry, Apr-05, Volume: 233Small-molecule inhibitors targeting small ubiquitin-like modifier pathway for the treatment of cancers and other diseases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (25.00)18.7374
1990's1 (6.25)18.2507
2000's9 (56.25)29.6817
2010's0 (0.00)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]